萬孚生物(300482.SZ):松山湖實業就“2020WT098地塊”簽署《國有建設用地使用權出讓合同》
格隆匯 12 月 16日丨萬孚生物(300482.SZ)公佈,公司的控股公司廣東萬孚松山湖實業有限公司(“松山湖實業”)近期通過“招拍掛”方式取得東莞市自然資源局掛牌的“2020WT098地塊”國有建設用地使用權。近日,松山湖實業與東莞市自然資源局簽署了《國有建設用地使用權出讓合同》(合同編號:東自然出讓(市場)合【2020】第154號)。
公司的控股公司松山湖實業取得相關國有建設用地使用權,固定資產總投資將不低於人民幣5.5億元,根據上市公司的發展需要進行新產業基地建設,保障上市公司中長期業務持續增長的需求,符合公司的中長期戰略規劃,對公司業務經營將產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.